Valeant Pharma (VRX) Sees 'Dead Cat Bounce' after CEO Hit with Margin Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Valeant Pharma (VRX) May Be Seeing Real Institutional Buying
November 6, 2015 1:32 PM ESTTalk on trading desks is that institutions are starting to accumulate Valeant Pharma (NYSE: VRX) today, nor just retail or short covering. This may be the first step in the recovery. Shares are up 5%.
... MoreGoldman sold 1.3 million Valeant shares backing loan to CEO, Valeant says
November 6, 2015 8:37 AM ESTNEW YORK (Reuters) - Goldman Sachs (NYSE: GS) sold 1.3 million shares of Valeant Pharmaceuticals International (NYSE: VRX) on Thursday, a day when the drug company's shares fell as much as 20 percent, because they were securing loans made to Valeant CEO Michael Pearson that needed to be paid.
Valeant said the sale was required by Goldman and had not been done at Pearson's request. Goldman declined to comment.
Valeant shares on Friday recovered some of Thursday's lost ground, gaining about 5.5 percent to $83.15. Valeant has been under... More
Valeant Pharma (VRX) 1.3M Shares Pledged on Behalf of Pearson Sold by Goldman Sachs
November 6, 2015 8:03 AM ESTValeant Pharmaceuticals International, Inc. (NYSE: VRX) stated today that 1,297,399 shares pledged to Goldman Sachs to secure loans made to chairman and chief executive officer J. Michael Pearson were sold by Goldman Sachs on November 5, 2015. Goldman Sachs held the shares as collateral for loans extended to Pearson.
As disclosed in the company's proxy statement filed on April 22, 2014, the company's board permitted... More
